Skip to content
Subscriber Only

Vivus Jumps as FDA Allows for Wider Sales of Obesity Drug

Vivus Inc. rose the most since March 6 after U.S. regulators said the drugmaker can sell its obesity pill Qsymia in more pharmacies than first allowed.

Vivus gained 5.6 percent to $11.78 at 4 p.m. New York time. The company had fallen by more than half since winning approval for the drug on July 17, as sales were slower than investors expected.